This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Histidine-rich glycoprotein.
Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Inhibits rosette formation.
Human | |
---|---|
Gene Name: | HRG |
Uniprot: | P04196 |
Entrez: | 3273 |
Belongs to: |
---|
No superfamily |
DKFZp779H1622; Histidine-proline-rich glycoprotein; histidine-rich glycoprotein; HPRG; HPRGHRGP; HRG
Mass (kDA):
59.578 kDA
Human | |
---|---|
Location: | 3q27.3 |
Sequence: | 3; NC_000003.12 (186665975..186678235) |
Expressed in macrophages and in malignant cells. Expressed by the liver and secreted in plasma (at protein level).
Secreted.
In this article, we'll discuss the benefits of Boster Bio's PLG Marker. This bioactive proteins inhibits angiogenesis, and bacterial antibodies GM-CSF/CpG. This information will allow you to decide if Boster’s HRG Marker is right in your research. You can also read on to learn about the HRG Marker's applications.
The Boster Bio HRG Marker is a highly sensitive and specific ELISA antibody, which has been extensively validated on Western Blotting, Immunohistochemistry, and ELISA. The antibody recognizes Ang K1-3 polypeptide chains containing 259 amin acids. It inhibits the growth and activity of tumor cells. It is highly specific and can be used for detecting and quantifying the presence of HRG tumors.
Boster Bio PLG Marker targets Ang K1-3, a nonglycosylated polypeptide that contains 259 amin acids. Cancer research and clinical trials aim to inhibit angiogenesis. The PLG antigen, which is a potent inhibitor and potential pathogen for ciVAX, is a potent inhibitor. Its mechanism of action remains unknown.
Boster Bio PLG Marker - (PLG) has been shown to inhibit bacterial Antigens CpG and, in certain experiments, GM - CSF. The protein is derived from a bacterial lysate and is encapsulated in biodegradable PLG microparticles. It was tested as a single injection in cattle in which the protein was mixed 50/50 with a large particle. The slow release of Sta-MP antibodies likely explains why the antibodies to Sta–MP supported phagocytosis in a lower level than the emulsified FIA protein. Additionally, the antibodies supported higher levels of phagocytosis than un.
Boster Bio PLG marker is an innovative biomaterial system that encapsulates bacterial antigens CpG, and GM-CSF. It can also act as a vaccine. It is a good choice as a pre-existing bacterial vaccination because it inhibits bacterial antigens CpG, GM-CSF. Its ability encapsulate these molecules makes it an attractive candidate for use across a range of clinical settings including the development vaccines and therapeutics.
The Boster bio PLG Marker is highly effective in osteosarcoma treatment. This marker is highly effective in treating osteosarcoma. It has the highest affinity for ECs. In experiments, it was shown that PAMPs from Enterobacter Cloacae can confer cross protection to E.coli and protect 77 per cent of mice. This is because PAMPs from this bacterium preserve epitopes.
The vaccine's PAMPs are bound to magnetic beads. These beads are combined in mesoporous Silica particles that are released depots GM – CSF. GM-CSF stimulates dendritic cell maturation. Once activated, the cells transfer PAMPs to a draining lymph node. There they interact with resident T and B cells. MPS particles act as potent inhibitors to angiogenesis.
The Boster Bio PLG Marker inhibits both CpG and GM-CSF in human cells. This antibody also blocks the activity TLR in bovine peripheral bone monocytes. It is also a potent inducer of IgA secretion in B cells. This product can be used to treat a wide range of diseases.
PMID: 3011081 by Koide T., et al. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA.
PMID: 8188234 by Hennis B.C., et al. Evidence for the absence of intron H of the histidine-rich glycoprotein (HRG) gene: genetic mapping and in situ localization of HRG to chromosome 3q28-q29.